8-K: CytomX Therapeutics Announces Positive Interim Phase 1 Data for CX-2051 in Advanced Colorectal Cancer and First Quarter 2025 Financial Results

CytomX Therapeutics reports encouraging interim Phase 1 data for CX-2051 in advanced colorectal cancer and details its Q1 2025 financial performance, extending its cash runway into Q2 2026.

Summary

• CytomX Therapeutics announced positive interim Phase 1 data for CX-2051 in advanced, late-line metastatic colorectal cancer (CRC).
• The data, as of April 7th, 2025, included results from 25 CRC patients treated with CX-2051 at doses ranging from 2.4 mg/kg to 10 mg/kg every three weeks.
• At higher doses (7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg), the overall response rate was 28%, with 5 out of 18 patients showing confirmed partial responses.
• The disease control rate at these doses was 94% (17/18 patients).
• Preliminary median progression-free survival was 5.8 months.
• CX-2051 was generally well-tolerated, with mostly Grade 1 or 2 treatment-related adverse events (TRAEs).
• The company has commenced CX-2051 dose expansions and expects to provide an additional Phase 1 data update in Q1 2026.
• A Phase 2 study in colorectal cancer is planned for initiation in the first half of 2026.
• CytomX ended Q1 2025 with $79.9 million in cash, cash equivalents, and short-term investments.
• This is expected to fund operations into the second quarter of 2026.
• Total revenue for Q1 2025 was $50.9 million, compared to $41.5 million in Q1 2024.
• Operating expense in the first quarter of 2025 was $28.3 million compared to $29.8 million in the first quarter of 2024.
• Astellas advanced the second program to GLP toxicology studies, triggering a $5.0 million milestone payment to CytomX.

Sentiment

Score: 7

Explanation: The document presents positive clinical data and financial results, but also acknowledges risks and uncertainties. The sentiment is cautiously optimistic.

Positives

• CX-2051 shows promising interim Phase 1 data in advanced CRC patients, with a notable response rate and disease control.
• The drug was generally well-tolerated in the study.
• The company has a clear plan to advance CX-2051 to Phase 2 trials in the first half of 2026.
• CytomX has a solid cash position of $79.9 million, providing a runway into the second quarter of 2026.
• Revenue increased in Q1 2025 compared to Q1 2024, driven by collaborations.
• Astellas milestone achieved triggered a $5.0 million payment to CytomX.
• Operating expenses decreased by $1.5 million year over year.

Negatives

• The company's cash position decreased from $100.6 million at the end of 2024 to $79.9 million as of March 31, 2025.
• Some patients experienced Grade 3 treatment-related adverse events, including diarrhea, nausea, fatigue, anemia, hypokalemia, neutrophil count decrease and neutropenia.
• The company incurred $2.9 million of one-time expenses related to the January 2025 restructuring.

Risks

• The success of CX-2051 and CX-801 is critical to the company's future.
• The company relies on third parties for manufacturing its product candidates.
• Clinical trials may not be successful.
• Regulatory developments in the United States and foreign countries could impact the company.
• The company may incur higher than expected research and development costs.
• The company may not obtain expected savings from the announced restructuring.
• The unproven nature of the company's PROBODY therapeutic technology.

Future Outlook

CytomX expects to provide an additional Phase 1 data update for CX-2051 in Q1 2026 and plans to initiate a Phase 2 study in colorectal cancer in the first half of 2026. The company believes its current cash resources will fund operations into the second quarter of 2026.

Management Comments

• Our positive interim clinical results announced today for CX-2051 in advanced colorectal cancer are highly encouraging and provide a significant opportunity for CytomX.
• CX-2051 remains the Company's top strategic priority and is positioned to rapidly advance towards later stage development.
• Just one year into the clinic, CX-2051 dose expansions are already in progress with a goal to initiate a Phase 2 study in advanced CRC in the first half of 2026.
• This excellent progress underscores the intense focus of the CytomX team on diligent execution for the benefit of the patients we serve, said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX.

Industry Context

The development of CX-2051, an EpCAM-directed ADC, addresses the unmet need in colorectal cancer treatment. The PROBODY technology represents a novel approach to cancer therapy by conditionally activating biologics in the tumor microenvironment, potentially leading to safer and more effective treatments. CytomX's collaborations with major pharmaceutical companies like Bristol Myers Squibb, Amgen, and Moderna highlight the industry's interest in this technology.

Comparison to Industry Standards

• The 28% overall response rate observed in the CX-2051 Phase 1 trial is promising compared to historical response rates for late-line colorectal cancer treatments.
• For example, single-agent chemotherapy in similar patient populations often yields response rates in the 10-20% range.
• The 94% disease control rate is also notable, suggesting that CX-2051 may provide clinical benefit even in patients who do not achieve a complete or partial response.
• Companies like Immunogen are also developing ADCs, and CytomX's collaboration with them on CX-2051 leverages Immunogen's expertise in ADC technology.
• The median progression-free survival of 5.8 months is competitive with other targeted therapies and chemotherapies used in this setting.

Stakeholder Impact

• Shareholders may react positively to the promising clinical data and extended cash runway.
• Employees may be reassured by the company's financial stability and progress in clinical development.
• Patients with advanced colorectal cancer may benefit from the potential advancement of CX-2051.
• Collaborators may be encouraged by the progress of partnered programs.

Next Steps

• Continue CX-2051 dose expansions at the 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg doses.
• Provide an additional Phase 1 data update for CX-2051 in Q1 2026.
• Initiate a Phase 2 study of CX-2051 in colorectal cancer in the first half of 2026.
• Continue Phase 1 dose escalation for CX-801 in metastatic melanoma.
• Initiate combination therapy with CX-801 and KEYTRUDA in 2025.
• Present initial Phase 1a translational and biomarker data in advanced melanoma for CX-801 in the second half of 2025.

Key Dates

Keywords

CX-2051, Colorectal Cancer, PROBODY, CX-801, Clinical Trials, Financial Results, CytomX Therapeutics, EpCAM ADC, Phase 1 Data, Q1 2025